CG Oncology (NASDAQ:CGON) Director Sells $92,000.00 in Stock

CG Oncology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Leonard Post sold 1,000 shares for $92,000, cutting his direct stake by 50% to 1,000 shares.
  • CG Oncology shares fell 6.9% to $78.94 in Tuesday trading, despite reporting a quarterly loss smaller than analysts expected and revenue above estimates.
  • Its preliminary Phase 3 PIVOT-006 results showed a 68% reduction in bladder-cancer recurrence risk; however, the therapy remains investigational, and FDA approval and filing plans are uncertain.
  • Interested in CG Oncology? Here are five stocks we like better.

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the business's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $92.00, for a total transaction of $92,000.00. Following the transaction, the director directly owned 1,000 shares of the company's stock, valued at approximately $92,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CG Oncology Stock Down 6.9%

CGON stock traded down $5.84 during mid-day trading on Tuesday, reaching $78.94. 3,160,872 shares of the stock traded hands, compared to its average volume of 1,153,223. The firm has a market capitalization of $7.05 billion, a PE ratio of -28.60 and a beta of 0.35. The business has a 50-day moving average of $68.24 and a two-hundred day moving average of $66.70. CG Oncology, Inc. has a 52 week low of $37.01 and a 52 week high of $93.95.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The business had revenue of $1.60 million during the quarter, compared to analysts' expectations of $0.55 million. On average, equities research analysts anticipate that CG Oncology, Inc. will post -3.00 EPS for the current fiscal year.

Institutional Trading of CG Oncology

A number of hedge funds have recently modified their holdings of the company. Fiduciary Financial Advisors acquired a new stake in shares of CG Oncology during the 2nd quarter worth approximately $28,000. Manchester Capital Management LLC raised its stake in shares of CG Oncology by 2,895.5% in the third quarter. Manchester Capital Management LLC now owns 659 shares of the company's stock valued at $47,000 after purchasing an additional 637 shares in the last quarter. Covestor Ltd lifted its position in CG Oncology by 72.6% in the third quarter. Covestor Ltd now owns 770 shares of the company's stock worth $55,000 after purchasing an additional 324 shares during the period. GAMMA Investing LLC lifted its position in CG Oncology by 47.9% in the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company's stock worth $77,000 after purchasing an additional 350 shares during the period. Finally, Fifth Third Bancorp acquired a new stake in CG Oncology during the first quarter worth $74,000. Institutional investors own 26.56% of the company's stock.

Top CG Oncology Stories

These are some of the CGON stories that stood out recently:

  • Positive Sentiment: Cretostimogene cut bladder-cancer recurrence risk by 68% in the Phase 3 PIVOT-006 trial (hazard ratio 0.32; p<0.0001), meeting its primary endpoint. The company reported no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results could expand the drug’s reach to an estimated 50,000-patient group for which no FDA-approved adjuvant treatment is available. Reuters article
  • Positive Sentiment: CG Oncology expects to submit a BLA for intermediate-risk and high-grade Ta disease in Q2 2027, and plans to broaden its initial BLA for BCG-unresponsive disease, with that submission expected by March 2027. The expanded potential market and promising data helped drive investor enthusiasm. Company announcement
  • Negative Sentiment: The PIVOT-006 results are topline and preliminary; approval, the breadth of any FDA label, and the planned filing timelines remain uncertain. The therapy is investigational and has not been approved by the FDA.

Analysts Set New Price Targets

Several research firms have recently weighed in on CGON. Truist Financial reissued a "buy" rating and issued a $100.00 price objective (up from $85.00) on shares of CG Oncology in a research report on Tuesday. HC Wainwright boosted their target price on shares of CG Oncology from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday. Guggenheim cut their target price on shares of CG Oncology from $90.00 to $89.00 and set a "buy" rating for the company in a research note on Monday, November 9th. Piper Sandler increased their price target on shares of CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Royal Bank Of Canada lowered shares of CG Oncology from an "outperform" rating to a "sector perform" rating and raised their price target for the stock from $80.00 to $97.00 in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CG Oncology presently has an average rating of "Moderate Buy" and a consensus target price of $96.11.

Check Out Our Latest Analysis on CG Oncology

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Read More

Insider Buying and Selling by Quarter for CG Oncology (NASDAQ:CGON)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CG Oncology Right Now?

Before you consider CG Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.

While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines